Concepedia

Gregory N. Dietsch

GN

24

Publications

1.8K

Citations

21

H-Index

1991

Active since

Affiliations

EKOS Corporation(Current)

University of Washington

Johns Hopkins University

Fred Hutch Cancer Center

Kindeva Drug Delivery (United States)

Gregory N. Dietsch is an author at EKOS Corporation specializing in medicine, immunology, and inflammation.

Top concepts

Publications per year

1991–2018

24

Publications

24

Chemokine expression in murine experimental allergic encephalomyelitis

Ronald Godiska, David Chantry, Gregory N. Dietsch et al. · Journal of Neuroimmunology · 1995 · 356 citations

, , +6

VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

Hailing Lu, Gregory N. Dietsch, Maura-Ann H. Matthews et al. · Clinical Cancer Research · 2011 · 170 citations

The Role of Recombinant Platelet-Activating Factor Acetylhydrolase in a Neonatal Rat Model of Necrotizing Enterocolitis

Michael S. Caplan, Matthew Lickerman, Luba Adler et al. · Pediatric Research · 1997 · 130 citations · Full text

, , +4

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

Laura Q.M. Chow, Chihiro Morishima, Keith D. Eaton et al. · Clinical Cancer Research · 2016 · 125 citations

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck

Robert L. Ferris, Nabil F. Saba, Barbara J. Gitlitz et al. · JAMA Oncology · 2018 · 108 citations · Full text

Rows per page

1–5 of 24